Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | CPX-351 for high-risk AML

Thomas Cluzeau • 18 Jun 2020
EHA 2020
Leukemia CPX-351 Cytarabine Daunorubicin

Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, outlines therapies for poor-risk acute myeloid leukemia (AML), including CPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Thomas Cluzeau

Triplets with an azacitidine/venetoclax backbone in AML: targeted and mutation-agnostic approaches
12:07
Triplets with an azacitidine/venetoclax backbone in AML: targeted and mutation-agnostic approaches
Thomas Cluzeau • 20 Sep 2026
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
19:38
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
Gail Roboz et al. • 7 Oct 2026
Managing TP53-mutated MDS: current strategies and remaining therapeutic challenges
1:28
Managing TP53-mutated MDS: current strategies and remaining therapeutic challenges
Thomas Cluzeau • 13 Jun 2026
Recent advances in frontline treatment approaches for patients with LR-MDS
2:17
Recent advances in frontline treatment approaches for patients with LR-MDS
Thomas Cluzeau • 13 Jun 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals